ArticleFrontiers in cell and developmental biology2026
Efficacy and patient selection of consolidative thoracic radiotherapy following chemoimmunotherapy in ES-SCLC.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite significant progress with immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC), progression-free survival (PFS) remains limited, and relapse is common. Whether consolidative thoracic radiotherapy (cTRT) administered after first-line chemoimmunotherapy offers additional clinical benefit remains uncertain, and the lack of clear patient selection criteria further restricts its application in real-world. Methods: ES-SCLC patients who received first-line PD-1/PD-L1 inhibitor plus platinum-etoposide and achieved disease control were included. All patients were divided into two groups based on whether they received cTRT. The primary endpoint was PFS. Secondary endpoints included overall survival (OS), depth of response (DpR), and safety. Results: A total of 91 patients were included. DpR analysis showed a higher incidence of additional tumor shrinkage in the cTRT group ( Conclusion: The cTRT following chemoimmunotherapy was associated with a higher incidence of additional tumor shrinkage and was independently related to longer survival. Prospective randomized trials are needed to identify the optimal efficacy and patient selection criteria for cTRT practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.